Brief: Kedrion And Kamada Announce FDA Approval Of Kedrab® Label Update, Confirming Safety And Effectiveness In Children
02/06/2021 12:26
June 2 (Reuters) - Kamada Ltd KMDA.TA :
* KEDRION AND KAMADA ANNOUNCE FDA APPROVAL OF KEDRAB® LABEL
UPDATE, CONFIRMING SAFETY AND EFFECTIVENESS IN CHILDREN
* KAMADA LTD - KEDRAB PRODUCT LABEL NOW INCLUDES PATIENTS OF
ALL
AGES
* KAMADA - LABEL EXPANSION DIFFERENTIATES KEDRAB AS FIRST
AND ONLY
HUMAN RABIES IMMUNE GLOBULIN AVAILABLE IN U.S. TO BE CLINICALLY
STUDIED IN CHILDREN
Source text for Eikon: ID:nGNXNcmyb
Further company coverage: KMDA.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kamada
See all newsBrief: Kamada Updates On Withholding Tax Procedures On Previously Announced Cash Dividend To Shareholders
Brief: Kamada Announces Planned Transition Of Chief Financial Officer
Brief: Kamada Q2 EPS USD 0.16
Brief: Kamada Announces FDA Approval Of Its New In-House Rabies Virus Neutralization Testing Laboratory
Brief: Kamada Q4 EPS USD 0.06